The Role of PTEN in Tumor Angiogenesis by Rodriguez, Stéphane & Huynh-Do, Uyen
Hindawi Publishing Corporation
Journal of Oncology
Volume 2012, Article ID 141236, 11 pages
doi:10.1155/2012/141236
Review Article
The Role of PTEN in Tumor Angiogenesis
Ste´phane Rodriguez and Uyen Huynh-Do
Department of Clinical Research and Department of Nephrology and Hypertension, Inselspital,
University of Bern Medical School, 3010 Bern, Switzerland
Correspondence should be addressed to Uyen Huynh-Do, uyen.huynh-do@insel.ch
Received 20 April 2011; Accepted 1 July 2011
Academic Editor: Sundaram Ramakrishnan
Copyright © 2012 S. Rodriguez and U. Huynh-Do. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
During the past 20 years, the phosphatase and tensin homolog PTEN has been shown to be involved in major physiological
processes, and its mutation or loss is often associated with tumor formation. In addition PTEN regulates angiogenesis not only
through its antagonizing effect on the PI3 kinase pathway mainly, but also through some phosphatase-independent functions. In
this paper we delineate the role of this powerful tumor suppressor in tumor angiogenesis and dissect the underlying molecular
mechanisms. Furthermore, it appears that, in a number of cancers, the PTEN status determines the response to chemotherapy,
highlighting the need to monitor PTEN expression and to develop PTEN-targeted therapies.
1. Physiological Angiogenesis
Vasculogenesis and angiogenesis are two distinct processes,
whereby the first represents vessel formation from differ-
entiated precursors while the second originates from the
preexisting vasculature. Capillaries formed during these
processes are mainly constituted by endothelial cells which
face the lumen of the vessel and sometimes, depending
on their size, are surrounded by mural cells comprising
pericytes and smooth muscle cells. Angiogenesis is essential
during development while in adulthood the vasculature is
usually quiescent, except during wound healing and the
female reproductive cycle [1]. It is governed by several
factors secreted by the targeted tissues and consists of four
steps. The first step originates from the existing vessel from
which the sprout arises. The combination of nitric oxide
and Vascular Endothelial Growth Factor (VEGF) enhances
vessel permeability by increasing capillary dilatation and
leakiness, respectively. This allows extravasation of various
plasma proteins which facilitate endothelial cell migration.
Second, endothelial cells, to invade the hypoxic tissue, have
to detach from the basement membrane they are laying on.
This is mediated by the secretion of proteases such as proteins
from the matrix metalloproteinase family (MMP-2, -3, -9)
or through the inhibition of protease inhibitors such as
TIMP (tissue inhibitor of MMP) proteins family. Third, after
endothelial cells have detached, they proliferate and migrate
to invade the hypoxic area, the source of proangiogenic
factors, until they find contact to another capillary. During
this process, as during axonal guidance, some cells lead the
elongation of the sprouting vessel towards the angiogenic
chemoattractant source. The endothelial cells forming the
sprouting blood vessels exhibit distinct phenotypes. We can
distinguish the tip cells at the leading edge of the sprout,
stalk cells which follow the tip and phalanx cells which are
quiescent cells from the mature vessel. Fate determination
of the tip cells is dynamically regulated by VEGF-A/VEGFR1
and 2 and Notch/Dll-4 signaling pathways. Briefly, endothe-
lial cells having the greater VEGFR2 to 1 ratio and higher
Dll4 expression are more likely to adopt and keep the
tip cell phenotype. VEGF-A-stimulated candidate cells will,
therefore, signal through VEGFR2 which has a lower affinity
for this ligand but a better protein kinase activity. VEGFR2
signaling leads to Dll-4 expression, activating Notch on the
neighbour cell. Notch signaling in these endothelial cells
leads to VEGFR1 upregulation while VEGFR2 is down-
regulated reducing the chance to become a tip cell. This
system results in fate determination of the tip cells while
keeping their neighbouring cells under a stalk cell phenotype;
however, these phenotypes are not fixed over time [2]. First,
the neighbourhood of tip cells is constantly changing due to
endothelial cell migration, and this impacts on cells’ VEGFRs
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expression. Second, VEGFR2 to 1 ratio determines the time
length of tip cell turnover, and, altogether, this result in an
oscillatory Dll4 expression. Third, the main source of VEGF-
Amay differs during vessel elongation. After formation of tip
cells, the sprout elongates through proliferation of stalk cells
and reaches its target under the drive of tip cells. During the
last step, cells start to differentiate and form a tube which
will be stabilized through the recruitment of mural cells
and secretion of extracellular matrix (ECM) [3]. An intact,
functional vasculature requires a right balance between
pro- and antiangiogenic factors; therefore, physiological
angiogenesis is the result of a tightly controlled excess
of proangiogenic factors. By contrast, tumor angiogenesis
(Figure 1) originates from a disturbed balance between
pro- and anti-angiogenic factors rendering endothelial cells
unable to become quiescent and consequently support a
constant growth of new blood tumor vessels [4]. In this
work, we will focus on the following factors involved in
tumor angiogenesis: VEGF/VEGFR, angiopoietins, and their
receptors: Tie-1 and -2, Eph receptors, and their ephrins
ligands, HIF1α (hypoxia-inducible factor 1 alpha), MMPs,
and delineate their relationship with the important tumor-
suppressor PTEN (phosphatase and tensin homologue).
2. Key Players in Angiogenesis
VEGF is the most important regulator of endothelial cell
fate and acts as ligand of the VEGF receptor which belongs
to the receptor tyrosine kinase (RTK) superfamily. VEGF is
phylogenetically ancient: in Drosophila it is thought to be
involved in blood cell positioning and comprises only one
member; however, in mammals, 5 members of the VEGF
family: VEGF-A, -B, -C, -D, and placenta growth factor:
PLGF have been described. VEGF-A plays a prominent role
in angiogenesis as shown by genetic studies of VEGF-A
knock-out mice which die embryonically [5]. VEGF-A inter-
acts preferentially with two of the three human members of
VEGF receptors: VEGFR1 (Flt-1) and VEGFR2 (Flk1), while
VEGF-B and PLGF bind to VEGFR1. Here we will not discuss
in details VEGF-C and -D, which bind to VEGFR3 (Flt-
4) and are involved in lymphangiogenesis. VEGF signaling
through VEGFR1 and -2 results in an upregulation of
proteases expression, recruitment of mural cells due to
PDGFβ secretion, increased vessel permeability, endothelial
cell proliferation, migration, survival, and specialization [6].
Angiopoietin (Ang) ligands bind to Tie receptors, which
are single transmembrane RTK. These proteins possess
three immunoglobulin-like (Ig-like) domains, three epithe-
lial growth factor domains (EGF) and three fibronectin type
III domains giving the name Tie: Tyr-kinase with Ig and EGF
homology domains. The two isoforms of Tie: Tie-1 and -
2 are involved in vascular development as demonstrated by
loss-of-function studies [7, 8]; however, Tie-2 is much more
studied than its isoform. Tie-2 is required early in embryonic
development for plexus remodeling and maturation. Tie-2 is
predominantly expressed on endothelial cells and principally
binds to Ang-1 and -2 which are agonist and antagonist
ligands, respectively. Ang-1 stimulation of Tie-2 leads to
endothelial cell survival and migration, limits vessel perme-
ability, and stimulates smooth muscle cells recruitment. Tie-
2 signaling triggers a negative feedback loop involving the
forkhead transcription factor FOXO1 and Ang-2 expression
[9].
Another system of receptor/ligand involved in angioge-
nesis regulation is the Eph/ephrin couple. Eph receptors (first
cloned from an erythropoietin producing hepatocellular
carcinoma cell line) belong to the RTK superfamily and are
involved in embryogenesis, axonal guidance, and angiogene-
sis [10–12]. Eph receptors are divided into two subfamilies:
A and B, which generally bind to ephrin A and B ligands,
respectively. In contrast to the other RTK whose ligands are
secreted molecules, ephrin ligands are membrane bound.
This renders this couple quite unique as (a) it requires two
neighbouring cells to signal, and (b) numerous studies have
demonstrated that this signal is transmitted by both receptor
and ligand. This bidirectional signaling is involved in the
regulation of the cytoskeleton leading to modulation of cell
adhesion, repulsion, and motility and contributing to cell
positioning [13]. Wang et al. first showed that EphB4 and
ephrinB2 are key players in the development of the vascular
system by the use of transgenic mice. They demonstrated
that EphB4 is restricted to veins while ephrinB2 is expressed
only by arteries, and a lack of one of these actors is
lethal due to perturbed arteriovenous differentiation [14].
Indeed ephrinB2 reverse signaling was demonstrated to
participate to tip cell guidance through control of VEGFR2
signaling guarantying a successful vasculature formation
[15]. Moreover, ephrinB2 was shown to contribute to vessel
maturation as it is expressed on mesenchymal cells such as
smooth muscle cells, and its binding to EphB leads to mural
cells recruitment [16].
As angiogenesis responds to an increased need in oxygen,
hypoxia is a crucial part of the process. The main effector of
the adaptive response to hypoxia is the transcription factor
HIF1. HIF1 is a member of the basic helix-loop-helix/PAS
protein transcription factor family and comprises HIF1α
and HIF2α, which to be active require heterodimerization
with HIF1β [17]. The α subunit acts as an oxygen sensor
as it is degraded under normoxia while the β subunit is
constitutively expressed. In normoxic condition, the prolyl
hydroxylase enzymes (PHD1-3) are in an active state and
hydroxylate HIF1α on two proline residues (402 and 564)
within its oxygen-dependent degradation domain (ODD)
[18]. Hydoxy-HIF1α is recognized by the complex formed
by the ubiquitin ligase VHL (von Hippel-Lindau) and the
elongin proteins, and this binding triggers the rapid HIF1α
degradation through the proteasomal pathway. In contrast,
under hypoxic conditions, HIF1α forms a heterodimer with
HIF1β, and their translocation to the nucleus acts on gene
expression through their binding to the hypoxia response
element (HRE). Numerous genes are regulated by HIF1,
some related to red blood cell production (erythropoietin),
some to the vascular architecture and tone (VEGF, VEGFR1,
or Nitric Oxide Synthase 2), some to the metabolism (Glut-
1 and Glut-3), and some to cellular proliferation and
differentiation (TGFβ, Cyclin G2, or p21) [19]. In 2005 our
group demonstrated an upregulation of EphB4, ephrinB2,
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Figure 1: Molecular basics of tumor angiogenesis. Key players of tumor angiogenesis and their main functions are depicted here. (a) Once
a tumor has reached a volume of 1-2mm3, tumor cells start to be hypoxic, and HIF1α is stabilized. Activated HIF pathway leads to the
expression of several genes (within green square) which greatly contribute to VEGF production. VEGF amplify this system through VEGF-
dependent MMPs expression involved in ECM degradation and growth factors release. VEGF acts as a chemoattractant on endothelial
cells from the nearest vessels and triggers vessel sprouting. Stimulated VEGFR2 leads to the expression of Dll4, a Notch ligand which
inhibits the tip cell transformation through VEGFR1 upregulation. VEGFR activation mediates proteases expression, VE-Cad complex
disruption leading to cell/cell and cell/matrix detachment. In parallel, Tie2 stimulation by Ang2 induces pericytes detachment. This step is
required for endothelial cell migration and proliferation. (b) While tip cells drive vessel elongation towards the source of VEGF and through
EphB4/ephrinB2 signaling, tumor cells attract stromal cells. These stromal cells, comprising tumor-associated macrophages (TAM) and
fibroblasts contribute to tumor angiogenesis through secretion of proangiogenic factors. During vessel elongation, new ECM is synthesized,
and few pericytes will cover the neovessel. This—in conjunction with NO production and disruption of adherens junctions—results in a
leaky vessel. (c) The resulting vasculature is tortuous with many dead ends and is prone to cell extravasation. Moreover, endothelial cells
contribute to tumor growth by secreting supporting molecules in addition to carrying nutrients and oxygen.
EphA2, ephrinA1 mRNA and protein expression in hypoxic
tissues [20].
Finally, one of the major sources of angiogenic factors is
the ECM, first because it can store growth factors such as
VEGF, second because degradation of some of its component
leads to the formation of pro- or anti-angiogenic factors.
Among the proteases involved in the release of such factors,
MMP proteins which are members of a zinc-dependent
family of endopeptidases and more precisely MMP2 and
9 are key players. MMP9 was shown to be activated in
numerous cancers and to contribute to tumor angiogenesis
by increasing the bioavailability of VEGF, basic fibroblast
growth factor (bFGF) by degrading collagen types IV, XVIII
and perlecan [21, 22]. Moreover, MMPs are involved in
cell migration by interfering with the cell-ECM and cell-cell
interactions.
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3. Tumor Angiogenesis
All the factors mentioned above are not only involved
in physiological but also in tumor angiogenesis. Tumor
development is first limited to 1-2mm3 due to the lack of
oxygen, nutrients, and growth factors. This restriction may
be the cause of tumor latency until the so-called angiogenic
switch occurs. Angiogenic switch is defined as the acquisition
by tumor cells of properties required for their unopposed
growth, where the balance is skewed towards a proangiogenic
phenotype [28]. As tumor cells are in a hypoxic state prior
to the angiogenic switch, the HIF1 pathway is constitutively
active and leads to the expression of angiogenesis-related
genes (VEGF/VEGFR, MMPs, Eph/ephrins). Noteworthy,
even after the tumor vasculature is fully developed and
functional, most of the tumor cells still maintain an activated
HIF1 pathway [29]. As mentioned earlier, HIF1 target
genes will lead to endothelial cell recruitment to the tumor
site mainly through VEGF/VEGFR activity. This effect is
amplified by tumor cells, which also have the capability to
attract stromal cells as cancer-associated fibroblasts (CAF)
[30] and tumor-associated macrophages (TAM) [31]. TAMs
seem to play a pivotal role as they secrete VEGF, MMP9, and
even immunosuppressive molecules. The resulting vessels
are often dilated due to VEGF and leaky because of nitric
oxide overproduction and deficient mural cell recruitment
[32]. Tumor vessels are characterized by their irregular
and tortuous shape consecutive to aberrant endothelial cell
proliferation and often possess dead ends leading to a higher
risk of hemorrhage. Therefore, a high tumor-associated
microvascular density does not reflect high oxygen level in
the tumor as blood flows only irregularly through tumor
vessels, leading to hypoxic areas within the tumor. Beside
the angiogenic factors directly depending on HIF1 pathway,
Ang-2/Tie and Eph/ephrins receptor/ligand pairs have also
been shown to play a role during the angiogenic switch.
Cancer-dependent Ang-2 upregulation occurs principally in
tumor-associated endothelial cells and can be used as a
biomarker of tumor progression [33]. High levels of Ang-2
trigger endothelial cells apoptosis mediating vessel pruning.
This leads to the formation of hypoxic area which in turn
upregulates VEGF expression and results in higher vascular
density [34]. The roles of EphB4 and ephrinB2 expressed
on blood vessels are more controversial. Although several
reports showed that EphB4 stimulation impairs tumor
growth due to a defect in tumor angiogenesis [35, 36], Kumar
et al. demonstrated the opposite [37–39]. Concerning ephrin
reverse signaling, Martiny-Baron et al. demonstrated that
blocking ephrinB2 stimulation by the use of monomeric
soluble EphB4 impaired tumor growth in nude mice and
correlates with a decreased microvessel density [40].
4. PTEN and Tumor Angiogenesis
A remarkable property of tumor angiogenesis is that all
involved factors described earlier signal through the PI3
Kinase (PI3K) pathway [41–44]. The PI3K pathway is a
signaling route involved in many cellular processes such
as cell survival, proliferation, or migration. The PI3K
protein class IA is activated in response to RTK sti-
mulation, while the class IB is activated by G-protein-
coupled receptors [45]. PI3K activation leads to the trans-
formation of phosphatidylinositol-4,5-bisphosphate (PIP2)
into phosphatidylinositol-3,4,5-trisphosphate (PIP3). This
in turn will activate Akt, a serine-threonine protein kinase
which has numerous targets comprising the mammalian
target of rapamycin (mTOR), a protein complex stimulated
in hypoxic and nutrient-poor environment. The major
regulator of this signaling pathway is PTEN, also known as
MMAC1 (Mutated in Multiple Advanced Cancer1) or TEP1
(TGFβ-regulated and epithelial cell-enriched phosphatase).
PTEN gene in human locates on chromosome 10q23.3
and encodes protein of 40–50 kilodaltons as in many
organisms, with the exception of PTEN from Caenorhabditis
elegans. This protein comprise 4 domains: at the N terminal
a PIP2 binding site, then a phosphatase domain, a C2
domain containing phosphorylation sites, followed by a PDZ
binding motif at the C-terminal end [46]. PTEN acts as
a phosphatase on both lipids and proteins; it antagonizes
PI3K pathway by transforming PIP3 into PIP2 (Figure 2)
[47] and dephosphorylates proteins such as SHC or FAK
[48, 49]. Several studies also report a role for PTEN in cell
migration, independent of its phosphatase activity as the
expression of a truncated form of PTEN possessing only the
PTEN C2 domain inhibits cell migration [50, 51]. PTEN
is regulated posttranscriptionally by miRNA, such as miR-
21 [52] and posttranslationally through phosphorylation,
acetylation, ubiquitylation, or by regulation of its localization
[53]. As the PI3K pathway is activated during angiogenesis,
PTEN can be considered as a major intracellular regulator of
this process.
Before discussing the role of PTEN in tumor endothelial
cells, we will first summarize its functions in cancer cells.
PTEN is frequently found deleted, mutated, or downre-
gulated in human malignancies. PTEN mutation primarily
affects the PTEN phosphatase domain and leads to se-
veral diseases including Cowden’s and the Bannayan-Riley-
Ruvalcaba syndrome, the Lhermitte-Duclos disease, as well
as an increased risk of breast, thyroid, and endometrial
cancers (Table 1).
Regarding HIF1, PTEN was found to inhibit its stabiliza-
tion and its transcription factor activity in glioblastoma cell
lines [54]. Moreover, several studies report a concomitant
loss of VHL and PTEN, two important regulators of the
HIF1 pathway, in clear cell renal cell carcinoma [55, 56].
Since HIF1 signals through PI3K pathway, leading to an
increased VEGF expression, PTEN loss in cancer cells
leads to an increased VEGF expression due to upregulation
of HIF1. This was shown by several investigators using
different models: Fang with PC-3 cells [57], Tian with
HepG2 cells [58]. Takei et al. [59] demonstrated that PTEN
reintroduction led to a decreased HIF1-α, VEGF, and PCNA
expression in ovarian cancer cells. As to MMPs, a study
using a multiple myeloma cell line and cells originating
from patients showed that PTEN transfection results in a
decreased mRNA and protein expression of MMP2, MMP9
and FAK (Focal Adhesion Kinase), leading to decreased cell
migration [60]. Furthermore, microarray analysis of gastric
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Figure 2: The PI3 kinase pathway and PTEN.
Table 1: PTEN-related diseases and associated cancer susceptibility. Percentages are indicated when available.
Disease PTEN defect Clinical symptoms Cancer susceptibility
Cowden’s syndrome
[23, 24]
Splice variants
Trichilemmonas,
macrocephaly,
papillomatous
papules
Breast (65%), thyroid
(75%), endometrium
(5–10%)
Deletion: coding sequence
promoter (10%)
Nonsense mutation
Missense mutation (85%):
C124: no phosphatase activities, G129: no lipid phosphatase
activity, K289: no nuclear translocation
The Bannayan-Riley-
Ruvalcaba syndrome
[23, 24]
Deletion (11%) Macrocephaly,
intestinal polyposis,
developmental delay,
lipomas, speckled
penis in male
Breast, thyroid,
endometrium, rare
colorectal carcinoma
Nonsense mutation
Missense mutation (60%)
The
Lhermitte-Duclos
disease [25]
Splice variants Ataxia, increased
intracranial pressure,
seizures Not demonstrated
Deletion
Nonsense mutation
Missense mutation (80%)
Proteus/Proteus-like
syndrome [26]
Missense mutation (20 and 50%, resp.)
Epidermal nevus,
disproportionate
overgrowth of the
skull, limbs,
vertebrate, Lipomas,
vascular
malformation
rare events:
cystadenoma of the
ovary, testicular
tumors, central
nervous system
tumors, parotid
monomorphic
adenomas
Autism [27] Missense mutation (around 10%)
Sometimes associated
with macrocephaly
Not demonstrated
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carcinomas highlighted a negative correlation between PTEN
expression and VEGF, MMP2, and MMP9 expression,
and the authors concluded that PTEN has an inhibitory
effect on microvascular density [61]. PTEN loss at post-
transcriptional level is also involved in tumor angiogenesis.
Giovannetti et al. [62] reported that in pancreatic ductal ade-
nocarcinoma, miR-21 is responsible for elevated expression
of MMP2, MMP9, and VEGF and this could be abrogated
by treatment of the cells with a PI3K inhibitor. As miR-21 is
overexpressed in many tumors, this strategy may represent a
valuable tool to control tumor angiogenesis [63]. Concerning
the Ang/Tie system, it was shown that Ang-1 stimulation
of Tie-2 triggers PI3K pathway activation [64]. Moreover,
Findley et al. described a Tie2 receptor shedding which
is able to bind Ang-1 and -2 and consequently inhibits
Tie2 phosphorylation and activation [65]. This process is
regulated by VEGF-dependent activation of PI3K pathway,
and PTEN overexpression increases Tie-2 shedding.
PTEN localization within the cell is also part of PTEN
regulation, since defective PTEN translocation to the cell
membrane impairs its control of PI3K signaling [87]. This
was shown by Molina et al., who found that the adaptor
protein NHERF1 is involved in PTEN translocation to the
cell membrane [88]. They proved that impaired PTEN
positioning leads to sustained Akt activation. This can be
of primarily importance as NHERF1 has been shown to
interact with several RTK such as PDGFRβ and EGFR [89,
90], which all play a role in tumor angiogenesis. Moreover,
PTEN translocation to the cell membrane is not solely
involved in regulation of RTK’s downstream signaling, but
is also emerging as a modulator of their expression [91].
Recent work from our lab has shown that PTEN also
interacts with EphB1 signaling (manuscript submitted). As
mentioned above, Eph receptors and ephrins are frequently
overexpressed by cancer and tumor endothelial cells, and
this may lead to an enhanced tumor angiogenesis. Among
the various pathways activated by Eph receptors, PI3K has
been reported in a number of studies [13, 92]. Moreover,
Brisbin showed a direct linkage between VAB-1 and DAF-
18, the C. elegans form of Eph and PTEN, respectively
[93], an interesting observation in line with our findings.
As during tumor angiogenesis both cancer and endothelial
cells are involved, PTEN status in endothelial cells is also
crucial. Many studies have shown that PTEN expression
can be disturbed in both stromal cells and endothelial
cells [94, 95]. This can be primordial as reduced PTEN
signaling in endothelial cells as well as PI3K activation leads
to an enhanced cell proliferation, survival, and migration—
all important features for angiogenesis [96–98]. Moreover,
tumor vessels are characterized by their inability to become
quiescent, and it was recently shown that PTEN is involved
in endothelial cell aging [99].
Interestingly, PTEN is susceptible to oxidation. As highly
proliferative cells overproduce reactive oxygen species (ROS),
this mechanism may account for the reduction of PTEN
levels in cancer and cancer-related cells [100]. A vicious
circle, therefore, begins as cancer cells produce more ROS,
affecting PTEN level and enhancing VEGF secretion [101,
102]. VEGF in turn acts on endothelial cells and stimulates
ROS production mainly by NOX1 (NADPH Oxydase 1)
[103], potentially affecting PTEN level as well as cell proli-
feration. VEGF will also amplify endothelial cell migration
and contribute to the angiogenic switch enhancing tumor
growth [104]. Another derivative of oxygen is NO, which
also plays a role in angiogenesis as it contributes to vessel
dilatation. Church et al. demonstrated that PTEN is involved
in endothelial Nitric Oxide Synthase regulation in both
cancer and endothelial cells [105] and should, therefore,
affect tumor angiogenesis.
Cancer cells have a supportive effect on endothelial
cells; however, the reverse is also true, with the formation
of the so-called vascular niche. Koistinen et al. demon-
strated that VEGF-stimulated endothelial NO production
maintains Acute Myeloid Leukemia (AML) cell growth, and
this involved the PI3K pathway [106]. Several examples of
endothelial cells stimulating solid tumor growth have also
been described. VEGF promotes endothelial cell survival
through PI3K activation and increased expression of the anti-
apoptotic protein Bcl-2, and this can be antagonized by an
increased PTEN expression [107]. Recently, it was shown that
Bcl-2-expressing endothelial cells also produce IL-8, which
acts on tumor cells and leads to an increased invasiveness
and metastatic ability [108]. Finally Park et al. demonstrated
that Nerve Growth factor (NGF) stimulates endothelial cells
to produce MMP2, a process inhibited by PTEN transfection
[109].
5. Anti-tumor Therapies and PTEN
It now clearly appears that PTEN is involved in all the diffe-
rent steps leading to tumor angiogenesis. As a consequence,
although the PI3K pathway is considered as the major
signaling node in physiological and tumor angiogenesis,
PTEN can be seen as the main intracellular antagonist to
this process. Many efforts have been made to control tumor
angiogenesis and related tumor growth, but here again PTEN
status appears to be critical [110, 111]. Initial strategies
to restrict tumor-associated angiogenesis used anti-VEGF
compounds such as monoclonal antibodies against VEGF-
A (Bevacizumab) or VEGFR tyrosine kinase inhibitors
(Sorafenib, Sunitinib). However, after promising results in
clinical trials, tumor resistance to these treatments has
emerged as a major problem. These resistances are often
related to a switch from VEGF- to bFGF- or EGF-dependent
angiogenesis and require the HIF-1α and PI3K pathways
signaling [112–114]. Many studies have now confirmed that
resistance to anti-EGFR therapies is often linked to PTEN
status in cancer cells, and PTEN loss negatively correlates
with clinical response to these therapies [115, 116] or others
(Table 2). This problem can be overcome by the use of com-
bined therapies which show synergistic effects and are now
tested in clinical trials [117, 118]. MMPs overexpression is
another resistance mechanism. We previously discussed the
negative correlation between PTEN and MMPs expression;
therefore, cancer cells with reduced or lost PTEN activity
are more prone to develop this kind of resistance. To avoid
the emergence of such resistance, different strategies aiming
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Table 2: Clinical trials having shown an impact of the PTEN status on the response to cancer treatment.
Type of cancer Metastatic form Treatments References
Colorectal
Cetuximab, panitumab [66–69]
× Cetuximab (+irinotecan) [70–72]
Breast
Trastuzumab, lapatinib [73–76]
×
Trastuzumab [76–78]
Endocrine therapy
Glioblastoma
Gefitinib, erlotinib [79–81]
Erlotinib + temozolomid
Gastric
Streptozotocin, doxorubicin, 5-fluorouracil, etoposide/cisplatinum [82, 83]
× Streptozotocin, doxorubicin [82]
Lung
Gefitinib, erlotinib [84, 85]
× Gefitinib, erlotinib [85]
Pancreas Gemcitabine [62]
Esophageal 5-fluoropyrimidine, taxane, platinum, PI3K pathway inhibitor [86]
at antagonizing the PI3K pathway or reintroducing the
expression and/or activity of PTEN have been tried. Many
PI3K inhibitors, as well as Akt and mTOR inhibitors, are
now being tested in clinical trials [119, 120]. Although there
are numerous inhibitors of the PI3K pathway, to date no
PTEN inducer has been found, explaining why only PTEN
transfection or gene therapy has been tried. Transfection of
wild-type PTEN into human prostate cancer cells sensitizes
cells to radiation and leads to a decreased tumor-induced
angiogenesis [121]. In this work, both cancer- and tumor-
associated endothelial cells were affected by this treatment.
As previously mentioned, PTEN reintroduction decreases
HIF-1α and VEGF levels [57–59], and Lee et al. showed
promising results using this strategy in mice [122]. As PI3K
inhibitors monotherapy has often shown mitigated results
and gene therapy experiments are just emerging, PTEN-
stimulating molecules are urgently needed. The greatest
challenge, however, remains the difficulty to set up a robust
PTEN activation model, where molecular stimulators of
PTEN could be tested.
6. Concluding Remarks
A myriad of studies have now demonstrated the central
role of the PI3K pathway in tumorigenesis and angiogenesis.
Overactivation of this pathway, a common event in cancer
cells, leads to enhanced and uncontrolled tumor angiogenesis
and can be antagonized by the phosphatase and tumor-
suppressor PTEN.Moreover, PTEN is involved in the control
of cell proliferation, migration, and survival of both cancer
and tumor-associated endothelial cells. Ideally, combining
PTEN-targeted therapy to classical chemotherapy should be
a promising strategy, leading to (a) normalization of the
tumor vasculature, (b) sensitization of cancer cells to further
chemo- and radiotherapy, and (c) avoidance of resistance
to such treatments. Further progress and development of
PTEN-targeted therapy are, therefore, required and may lead
to improvement of the current anticancerogenic strategies.
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